ECKERT ROBERT 4

What Happened

• Robert Eckert, a director of Amgen Inc., was granted 665 restricted stock units (RSUs) on May 19, 2026. The grant is reported at $0.00 per share (no cash paid) — typical for RSU awards — so reported cash consideration = $0. Vested RSUs are paid in shares of Amgen common stock on a one-for-one basis.

Key Details

• Transaction date: 2026-05-19; filing date (Form 4): 2026-05-21 (appears filed within the normal Section 16 reporting window).
• Grant: 665 RSUs @ $0.00 (reported acquisition via award).
• Shares owned after transaction: not specified in the provided excerpt.
• Footnotes:
  • F1: RSUs were granted under Amgen’s 2009 Director Incentive Program (Second Amended and Restated 2009 Equity Incentive Plan) and vested immediately; vested RSUs are paid one-for-one in shares and may be deferred by the director per an elected schedule.
  • F2: Filing notes dividend equivalents (DEs) are credited to unvested RSUs and are paid out in shares per the vesting schedule (the footnote references DEs and their treatment, including cash for fractional shares).

Context

• This transaction is an award/grant (not an open‑market buy or sale). Awards to directors are routine compensation and do not in themselves indicate a buy or sell signal by the insider.
• Because the RSUs vested immediately, Eckert will receive shares (unless he elected deferral) rather than exercising options or paying cash.